Wilson disease: Histopathological correlations with treatment on follow-up liver biopsies

Sandy Cope-Yokoyama, Milton J Finegold, Giacomo Carlo Sturniolo, Kyoungmi Kim, Claudia Mescoli, Massimo Rugge, Valentina Medici

AIM: To investigate the progression of hepatic histopathology in serial liver biopsies from Wilson disease (WD) patients.

METHODS: We report a group of 12 WD patients treated with zinc and/or penicillamine who underwent multiple follow-up liver biopsies. Demographic, clinical and laboratory data were gathered and all patients underwent an initial biopsy and at least one repeat biopsy.

RESULTS: Time to repeat biopsy ranged from 2 to 12 years. Six patients (non-progressors) showed stable hepatic histology or improvement. In one case, we observed improvement of fibrosis from stage 2 to 0. Six patients (progressors) had worsening of fibrosis. There was no significant correlation between the histological findings and serum aminotransferases or copper metabolism parameters. The hepatic copper concentration reached normal levels in only two patients: one from the non-progressors and one from the progressors group. The estimated rate of progression of hepatic fibrosis in the entire group was 0 units per year in the time frame between the first and the second liver biopsy (4 years), and 0.25 between the second and the third (3 years). In the progressors group, the rate of progression of liver fibrosis was estimated at 0.11 fibrosis units per year between the first and second biopsy and, 0.6 fibrosis units between the second and third biopsy.

CONCLUSION: The inability of clinical tools to detect fibrosis progression in WD suggests that a liver biopsy with hepatic copper quantification every 3 years should be considered.

© 2010 Baishideng. All rights reserved.

Key words: Wilson disease; Copper; Liver biopsy; Histopathology

Peer reviewers: Dr. Seyed Mohsen Dehghani, MD, Associate Professor, Department of Pediatrics, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran; Christopher O’Brien, MD, Professor of Clinical Medicine, Chief of Clinical Hepatology, Center for Liver Diseases, Divisions of Liver and GI Transplantation,
INTRODUCTION

Wilson disease (WD) is an inherited, autosomal recessive disorder of copper accumulation that affects about one individual per 30,000 population [1]. It is due to the dysfunction of a copper-transporting P-type ATPase that has a crucial role in copper excretion into the bile. The gene that encodes this P-type ATPase, ATP7B, is located on chromosome 13q14.3, and numerous gene mutations can impair the protein’s function [2,3], which leads to copper accumulation mainly in the liver, but also in the brain, cornea, and kidney. The most frequent clinical presentation of WD is liver involvement [4]. Hepatic manifestations may vary from hepatomegaly and fatty liver, to acute hepatitis, with high serum aminotransferases, liver failure, jaundice, and cirrhosis. The earliest morphological features of WD are represented by micro- and macrovesicular hepatic steatosis, glycogenated nuclei in the perportal hepatocytes, and focal hepatocellular necrosis. With the progression of parenchymal damage and inflammation, fibrosis, and subsequently cirrhosis, invariably develop. Cirrhosis can have either a micronodular or a mixed macro-micronodular pattern, and it is rarely complicated by hepatocellular carcinoma or cholangiocarcinoma [5]. Regarding the timing of the disease progression, cirrhosis is often diagnosed by the second decade, but there are some individuals who do not develop cirrhosis even after the fourth decade of life [6,7]. The ultrastructural analysis is characterized typically by mitochondrial abnormalities, including variability in size and shape, increased density of the matrix material, and numerous inclusions of lipid and fine granular material, which may be copper [8]. With adequate treatment, these changes may not occur. WD is a treatable disorder and early diagnosis is essential: the goal of therapy is to reduce copper accumulation by enhancing its urinary excretion (with chelating agents) and by decreasing its intestinal absorption (with zinc salts) [9,10]. As a result of the rarity of the disease and the fact that the liver biopsy is not performed routinely during the follow-up of WD, unless clinically indicated, the progression and timing of the liver pathology and its correlation with different anti-copper treatments or with aminotransferase levels are poorly characterized. Previous studies have shown the possibility of improvement of the steatosis and inflammation grade [11], and the fibrosis stage [12,13] during long-term follow-up. However, studies on serial liver biopsies, as well as studies on the correlation between hepatic histology and clinical parameters, are lacking.

The overall objective of this study was to describe the evolution of liver histology in WD patients during penicillamine (PCA) and zinc treatment, to define the rate of progression of the liver damage, and to correlate the clinical and biochemical parameters of liver injury with hepatic copper concentration.

MATERIALS AND METHODS

We included 12 patients with WD from the Division of Gastroenterology and Hepatology, Padua University Hospital (Italy), who were followed from 1981 to 2006 and who underwent serial liver biopsies. The mean follow-up was 5 ± 3 years (range: 1-12 years). Patients with history of alcohol abuse, positive serology for hepatitis B and C, and features of the metabolic syndrome were excluded. The study was conducted according to the principles of the Declaration of Helsinki, and all patients gave informed consent before undergoing liver biopsy. WD was diagnosed when 24-h urine copper excretion was > 100 μg/24 h, hepatic copper concentration was > 250 μg/g dry weight, and serum ceruloplasmin was < 20 mg/dL. All patients were treated with either PCA or zinc sulfate following the initial biopsy. Liver biopsy samples were obtained by the percutaneous route, using the Menghini method. Liver copper concentrations in dried liver tissue were measured by flame atomic absorption spectrophotometry. Demographic, clinical, and laboratory data were gathered, and all patients underwent an initial and at least one repeat biopsy. Selected laboratory values were recorded at the time of initial and repeat biopsies: serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), 24-h urinary copper excretion, and hepatic iron deposition throughout all zones [14]. Hepatic inflammation was 0, none; 1, mild; 2, moderate; and 3, severe. The grading of steatosis was 0, none; 1, up to 25%; 2, 25%-50%; 3, 50%-75%; and 4, 75%-100%. The staging of fibrosis was 0, none; 1, expansion of portal fibrous tissue; 2, early bridging, no nodules; 3, bridging fibrosis, early nodule formation; and 4, cirrhosis. Iron deposits were graded by a standard method, from 0 to 4, where grade 1 represents minimal iron deposition and grade 4 represents iron deposition throughout all zones [15]. Patients were separated into two groups. We considered as progressors the patients who presented worsening of at least one unit of fibrosis. Inflammation and steatosis were described separately. Non-progressors presented stable or improved fibrosis scores. The rate of the fibrosis progression was calculated as the result of the mean difference in fibrosis scores divided by the mean interval in years between the first and second liver biopsies.
Statistical analysis

Data are expressed as mean ± SD or as proportions. The goodness-of-fit test was used to determine whether the distributions of continuous variables were normal prior to analysis [16]. Measurements were log-transformed as necessary to improve the normality of residuals and homoscedasticity (or homogeneity of variance) of errors before analysis. Paired t test was used to compare the underlying mean differences in response between follow-up and baseline. Separate analyses were performed for each variable and each follow-up time. Analysis of variance (ANOVA) was performed to assess: (1) whether there was a significant mean difference in each response between two independent samples (i.e. treatment groups); and (2) whether there was a significant mean difference between progressors and non-progressors, after controlling the potential effects of other variables. Pearson (Spearman) correlation coefficients were estimated to assess the magnitude and direction of a linear association between two given continuous (ranked) variables. Individual trajectories of serum measurement changes in response level over the follow-up time were estimated from linear random-effect models. Each response level was entered as the dependent variable and treatment, follow-up time, and treatment × follow-up time interaction were entered as the independent variables. To account for inter-subject heterogeneity in the change of response level, intercept and time were modeled as random effects. A two-side P value of 0.05 was considered significant. All statistical analyses were performed using SAS, Version 9.1 (SAS Institute, Cary, NC, USA).

RESULTS

Clinical features

Table 1 summarizes the clinical features for progressors vs non-progressors. The mean age of the 12 patients at diagnosis was 17.3 years (range: 6-35 years), and three (25%) were female. Ten patients presented with different degrees of hepatic symptoms and two with mixed hepatic and neurological disease, mainly characterized by rigidity, tremors, and dystonia. At baseline, before anti-copper treatment, 24-h urinary copper concentration was 994 ± 1293 μg/g dry liver, and mean hepatic copper concentration was 491 ± 260 μg/g dry liver. Five patients were started on PCA after the diagnosis, and the remaining seven on zinc salts. Most patients remained on the same drug during follow-up. One patient began zinc treatment that was later changed to PCA, and the therapy switch was indicated by the lack of improvement of liver enzymes. At diagnosis, the mean ALT was 84.1 ± 50.9 U/L, and AST was 62.8 ± 50.5 U/L. During follow-up, we observed a significant improvement of aminotransferase levels, with mean ALT 37.3 ± 20.6 U/L and AST 35.3 ± 34.8 U/L (P = 0.01 and 0.03, compared to baseline) at the time of the second liver biopsy and mean ALT 38.3 ± 17 U/L and AST 27.9 ± 9.9 U/L at the time of the third liver biopsy. There was no significant change in hepatic copper concentration over time (Figure 1), and there was no significant difference in terms of laboratory data improvement between progressors and non-progressors (Table 1).

Hepatic histology

All patients underwent at least two liver biopsies. The average number of portal tracts was 14.9 ± 7.5 (range: 4-34). The mean interval between the first and the second liver biopsy was 4 years (range: 2-12 years) (12 patients). The mean interval between the second and third biopsy was 3 years (range: 2-4 years) (four patients). Two patients underwent a fourth liver biopsy after 2 and 3 years, respectively. None of the patients was on anti-copper treatment at the time of the first liver biopsy. The follow-up liver biopsies were indicated by an increase in the aminotransferase levels, or change of therapy, or were performed to monitor the potential disease progression. At baseline, five patients had grade 0 steatosis, three had grade 1, three had grade 2, and one presented with grade 3. Regarding the stage of fibrosis, seven had stage 0, three had stage 1, and two had stage 2. There were no cirrhotic patients. Three patients (two on zinc and one on PCA) showed overall improvement of the histological severity (patients 2, 3 and 6), with decreased steatosis (Figure 2A and B), and in one case, significant improvement of fibrosis, from stage 2 to 0 over 6 years of follow-up (Figure 2C and D). Three patients (one on zinc and two on PCA) showed no significant change in histology, although initial biopsies in this group showed mild lesions (patients 1, 4 and 5; Table 2). The patients with mixed neurological and hepatic phenotype were both included in the non-progressors group (patients 1 and 2). The six patients who manifested histological progression (patients 7-12) demonstrated worsening of inflammation and/or fibrosis (Figure 2E and F). Of these six patients, four had been started on zinc and two on PCA, and one was switched from zinc to PCA. One patient (#10) who showed an overall progression underwent the second liver biopsy 12 years after the first one, and over this time, the grade of steatosis and inflammation and the stage of fibrosis increased (Table 2).
Hepatic copper concentration was variable in the two groups, and did not correlate with histological findings. Progressors showed a mean hepatic copper concentration higher than non-progressors at all time points, but the result was not significant due to the small sample and high variability of the hepatic copper content (Figure 1).

In our study, the hepatic copper concentration reached normal levels (< 50 μg/g dry weight liver) in only two patients: one from the non-progressors group and one from the progressors group. The patients who did not show any change in histology also had consistent decreases in hepatic copper concentration, although levels were still elevated above normal. Iron staining was positive at baseline in two progressors and in one non-progressor. In one non-progressor the iron staining was positive after 4 years of anti-copper treatment (Table 2). There was no correlation between iron staining results and the severity of inflammation and fibrosis.

The histological progression did not correlate with subsequent aminotransferase levels or with the type of therapy. The estimated rate of progression of hepatic fibrosis (as result of the mean difference in fibrosis scores divided by the mean interval in years between the first and second liver biopsies) in the entire group was 0 units per year in the time frame between the first and the second liver biopsy, and 0.25 between the second and the third. However, among progressors, the rate of progression of fibrosis was estimated at 0.23 fibrosis units per year between the first and the second biopsy, and 0.6 units between the second and the third.

### Table 1  Baseline characteristics of patients who showed progression of the histologic score (progressors) vs those who showed overall improvement or no progression in histology (non-progressors)

|                      | Progressors                        | Non-progressors                      |
|----------------------|------------------------------------|--------------------------------------|
| Age at diagnosis (mean ± SD) (yr) | 18.0 ± 8.8                         | 16.6 ± 9.8                           |
| Phenotype            | All hepatic phenotype              | 4 with hepatic phenotype; 2 with mixed hepatic and neurological phenotype |
| AST U/L (baseline) (normal range 15-43) | 60.0 ± 56.8 (range 18-44) (6)       | 64.6 ± 51.3 (range 15-129) (6)       |
| AST U/L (time of 2nd biopsy)       | 45.1 ± 48.2 (range 20-143) (6)      | 25.5 ± 9.7 (range 13-39) (6)         |
| AST U/L (time of 3rd biopsy)       | 27.3 ± 10.2 (range 13-44) (6)       | 28.7 ± 10.8 (range 15-41) (3)        |
| AST U/L (time of 4th biopsy)       | 24 and 28 (2)                      |                                      |
| ALT U/L (baseline) (normal range 6-43) | 83.5 ± 40.2 (range 45-137) (6)    | 84.5 ± 60.7 (range 15-164) (6)       |
| ALT U/L (time of 2nd biopsy)       | 48.5 ± 21.8 (range 24-80) (6)       | 26.1 ± 12.3 (range 10-40) (6)        |
| ALT U/L (time of 3rd biopsy)       | 42.0 ± 17.2 (22 and 68) (2)         | 32.7 ± 17.2 (range 8-48) (3)         |
| ALT U/L (time of 4th biopsy)       | 47.0 ± 7.0 (42 and 52) (2)          |                                      |
| 24 h urinary Cu μg/24 h (baseline) | 679.7 ± 504.0 (6)                  | 1245.0 ± 1649.0 (6)                  |
| Hepatic Cu mg/g dry liver (baseline) | 534.4 ± 298.7 (6)             | 455.0 ± 245.3 (6)                   |
| Type of treatment               | 2 = penicillamine; 4 = zinc         | 3 = penicillamine; 3 = zinc          |
|                                  | One patient switched to penicillamine during follow up | No change of treatment during follow up |

The numbers in brackets represent the number of patients included in the analysis.
DISCUSSION

While our study confirms that, in WD, the clinical laboratory parameters do not correlate with the progression of hepatic histopathology, our newest finding is the rate of progression of fibrosis of 0.1 fibrosis units per year over a mean follow-up of 4 years after the diagnosis, and of 0.25 over 3 years between the second and third liver biopsy. We also observed improvement of the stage of fibrosis in two patients. Although some patients have been followed for several years, the overall amount of fibrosis in our study was low, with no patients demonstrating cirrhosis, even after long-term follow-up. However, our study covered a maximum of 12 years of follow-up, which might not be sufficient to observe the development of advanced-stage fibrosis in WD. A large study from Germany on 163 patients, 78 of whom underwent liver biopsy, showed variable hepatic involvement, with 37% patients presenting with cirrhosis, 36% with unspecified stage of fibrosis, and 54% with steatosis. Similar to our data, the hepatic copper concentration was highly variable, with a range from 95 to 3776 μg/g dry weight.

Our finding that anti-copper treatments, zinc and PCA, were equally distributed between progressors and non-progressors is in agreement with previous studies that have demonstrated various responses to different type of treatments, including PCA, trientine, and zinc. There are six main previous studies on follow-up liver biopsies including a total of 42 WD patients (Table 3). The effect of PCA in the long-term progression of liver damage in WD has been described in three small groups of patients: four pediatric patients showed improvement or stable hepatic fibrosis after 2-7 years of treatment, and seven adult patients showed marked improvement or disappearance of steatosis and improvement of mitochondrial morphological abnormalities after 3-5 years of PCA. Shiono et al. have described an improvement in chronic active hepatitis in one patient after 6 years of PCA treatment, while in two patients with cirrhosis, there was no significant change in histopathology after 3-8.5 years of follow-up. Marcellini et al. have described a pediatric population of 22 subjects that underwent a follow-up liver biopsy 10 years after diagnosis, and all subjects were treated with zinc sulfate. The

| Patient | Biopsy interval (yr) | Biopsy data | Iron staining | Treatment type |
|---------|----------------------|-------------|---------------|----------------|
|         |                      | Inflammation| Steatosis     | Fibrosis       |
| Group NP |                      |             |               |                |
| 1       | 0                    | 0           | 0             | None           |
| 2       | 1                    | 0           | 0             | None           |
| 3       | 2                    | 0           | 0             | None           |
| 4       | 3                    | 0           | 0             | None           |
| 5       | 4                    | 0           | 0             | None           |
| 6       | 5                    | 0           | 0             | None           |
| Group P |                      |             |               |                |
| 7       | 6                    | 0           | 2             | None           |
| 8       | 7                    | 1           | 1             | None           |
| 9       | 8                    | 2           | 1             | None           |
| 10      | 9                    | 2           | 0             | None           |
| 11      | 10                   | 2           | 0             | None           |
| 12      | 11                   | 2           | 0             | None           |

Grade of inflammation and steatosis are also described. Indicates the two patients who presented with mixed hepatic and neurological phenotype. NP: Non-progressors; P: Progressors; Zinc: Zinc sulfate; PCA: Penicillamine.
Table 3  Review of the case series describing the evolution of hepatic histology in WD

| Grand et al[18], 1975 | Treatment: PCA |
|----------------------|----------------|
| **Interbiopsy interval 2-7 yr** | **Hepatic copper (μg/g dry weight)** | **AST/ALT** | **Histopathology** | **Before** | **After** |
| **Age at diagnosis (yr)** | **Before** | **After** | **Before** | **After** |
| 1 | 24 | NA | 400 | NA | NA | Inflammation 3+; connective tissue 13%; fatty vacuolization 0.5% | Inflammation 1+; connective tissue 7%; fatty vacuolization 0.5% |
| 2 | 18 | NA | 80 | NA | NA | Inflammation 2+; connective tissue NA; fatty vacuolization NA | Inflammation 2+; connective tissue 3%; fatty vacuolization 2% |
| 3 | 11 | 1360 | 757 | NA | NA | Inflammation 3+; connective tissue 17.6%; fatty vacuolization 5% | Inflammation 0/1+; connective tissue 7.6%; fatty vacuolization 3% |
| 4 | 13.5 | 1112 | 90 | NA | NA | Inflammation 4+; connective tissue 16%; fatty vacuolization 13% | Inflammation 0; connective tissue 14%; fatty vacuolization 8% |

| Sternlieb et al[19], 1976 | Treatment: PCA |
|---------------------------|----------------|
| **Interbiopsy interval 3-5 yr** | **Hepatic copper (μg/g dry weight)** | **AST/ALT** | **Histopathology** | **Before** | **After** |
| **Age at diagnosis (yr)** | **Before** | **After** | **Before** | **After** |
| 1 | 15 | 821 | 109 | 52/59 | 39/20 | Mild fibrosis; steatosis | Mild fibrosis; marked diminution of steatosis |
| 2 | 9 | 1004 | 945 | 76/136 | 20/44 | Steatosis | Marked diminution of steatosis |
| 3 | 12 | 866 | 737 | 180/190 | 24/26 | NA | NA |
| 4 | 15 | 1123 | 239 | 22/94 | 16/22 | Severe steatosis | Resolution of severe steatosis |
| 5 | 10 | 832 | 453 | 57/88 | 53/48 | Inflammation; mild fibrosis; steatosis | Resolution of inflammation; mild fibrosis; diminution of steatosis |
| 6 | 12 | 1177 | 1050 | 65/85 | 45/43 | Inflammation; severe fibrosis and steatosis | Resolution of inflammation; diminution of severe steatosis and fibrosis |
| 7 | 14 | NA | NA | 75/82 | 50/35 | Inflammation; steatosis; cirrhosis | Diminution of steatosis and inflammation; persistence of cirrhosis |

| Shiono et al[20], 2001 | Treatment: PCA |
|-----------------------|----------------|
| **Interbiopsy interval 3-8.5 yr** | **Hepatic copper (mg/g dry weight)** | **ALT (IU/L)** | **Histopathology (only stage of fibrosis)** | **Before** | **After** |
| **Age at diagnosis (yr)** | **Before** | **After** | **Before** | **After** |
| 1 | 16 | 990 | 319 | 121 | 65 | Cirrhosis with chronic active hepatitis | Cirrhosis |
| 2 | 17 | 1025 | 945 | 241 | 109 | Chronic active hepatitis | Chronic inactive hepatitis |
| 3 | 19 | 524 | 190 | 17 | 25 | Cirrhosis | Cirrhosis |
| 4 | 23 | 540 | 129 | 19 | 18 | Cirrhosis | Cirrhosis |

| Marcellini et al[12], 2005 | Treatment: zinc sulfate |
|---------------------------|------------------------|
| **Interbiopsy interval 10 yr** | **Hepatic copper (median of 22 pts) (mg/g dry weight)** | **AST/ALT (mean of 22 pts)** | **Histopathology summary of 22 pts** | **Before** | **After** |
| **Age at diagnosis (yr)** | **Before** | **After** | **Before** | **After** | **Before** | **After** |
| Mean age at diagnosis (yr) | 6.1 ± 2.5 | 873 (670-982) | 690 (600-890) | 110/94 | 21.7/23.7 | Inflammation grade 1 in 81% of pts; grade 0 in 19%; steatosis grade 1 in 50%, grade 2 in 22.7%, grade 3-4 in 27.3%; fibrosis stage 1 in 54%, stage 3 in 46% | Resolution of inflammation in all pts; steatosis grade 1 in 90%, grade 2 in 10%, fibrosis stage 1 in 81%, stage 3 in 19% |

| Askari et al[13], 2003 | Treatment: trientine + zinc, followed by long-term zinc |
|-----------------------|-----------------|
| **Interbiopsy interval 4.4-10 yr** | **Hepatic copper (mg/g dry weight)** | **Child Pugh score (AST/ALT not available)** | **Histopathology (only stage of fibrosis)** | **Before** | **After** |
| **Age at diagnosis (yr)** | **Before** | **After** | **Before** | **After** |
| Mean age at diagnosis (yr) | 25.4 ± 3.9 | NA | NA | 9-13 | 5 | Cirrhosis | Fibrosis stage 2-3 |
| Linn et al[14], 2009 | Treatment: zinc |
|-----------------------|----------------|
| **Interbiopsy interval 3-7 yr** | **Hepatic copper (mg/g dry weight)** | **ALT (U/L)** | **Histopathology** | **Before** | **After** |
| **Age at diagnosis (yr)** | **Before** | **After** | **Before** | **After** |
| 1 | 21 | NA | 59 | 57 | Mild fibrosis | Normal |
| 2 | 13 | 1100 | 270 | 31 | Normal | Cirrhosis |
authors observed an improvement in all parameters of histological damage (inflammation, steatosis, and fibrosis) and an overall decrease in hepatic copper concentration; however, the level remained higher than normal in all patients. Askari et al. have shown various degrees of improvement of fibrosis in three WD patients with cirrhosis, who were treated first with zinc and trientine and later only with zinc as maintenance treatment. One patient showed persistent stage 3-4 fibrosis; a second patient showed stage 2-3 and only one showed stage 1. Linn et al. have described 17 patients who were followed for a median of 14 years and treated with zinc. In two cases, a second liver biopsy was performed after the baseline, which showed resolution of the initial mild fibrosis in one case and development of cirrhosis in the other. Although the data are heterogeneous and the progression of histopathological features is described following different criteria, it seems that there was an improvement in histology in most of the described patients, while we observed improvement or no progression only in 50% of cases. The explanation of our findings may be that we performed the liver biopsies when clinically indicated by the failure to respond to anti-copper agents, which potentially selected worse cases.

In previous work on WD, there have been variable changes in serum aminotransferases upon initiation of either PCA or zinc therapy, as well as persistently high levels resistant to either PCA or zinc therapy. In none of these studies was there a significant correlation between aminotransferase level and histological progression, which confirms the observation made by us and others that, in WD, an elevation of aminotransferase level is common and does not correspond to clinical worsening. The discovery of a higher hepatic copper concentration in progressors, as compared to non-progressors, is certainly not surprising and it may underline the importance of measuring hepatic copper during follow-up. Only one post-treatment specimen became positive for iron staining, and there was no correlation with fibrosis progression, which prevented us making any comparison with the results of Shiono et al., which showed hepatic iron accumulation after long-term anti-copper treatment. Our study was limited by the relatively small number of patients; however, this was still one of the largest studies conducted on serial biopsies of this rare condition. The limited statistical power did not allow us to find significant correlations or predictive factors of histological progression, but we were able to derive important observations that might contribute to the long-term management of WD, considering that the timing and the indication for follow-up liver biopsy in WD has not been established yet. Our patients were recruited in the hepatology setting and were selected for this study according to the availability of serial liver biopsies. Nevertheless these patients’ varied histopathology appears representative of the WD hepatic presentation. Our study focused on the role of liver biopsy in WD follow-up. However, liver biopsy, even as a fundamental diagnostic tool in WD and in chronic liver diseases, is limited by sampling error, which can affect both histological evaluation and hepatic copper concentration, which is known to be significantly variable over time and among regenerative nodules in WD cirrhosis. Despite these limitations, our data are particularly valuable because of the rarity of WD and the infrequency of serial liver biopsies in this disease. Our observation of the inability of clinical tools to detect the progression of fibrosis despite treatment suggests that a liver biopsy with hepatic copper quantification every 3 years should be considered.

**COMMENTS**

**Background**

The earliest morphological features of Wilson disease (WD) are represented by micro- and macrovesicular hepatic steatosis, glycogenated nuclei in the perihilar hepatocytes, and focal hepatocellular necrosis. With the progression of parenchymal damage and inflammation, fibrosis, and subsequently, cirrhosis invariably develop. As a result of the rarity of WD and the fact that liver biopsy is not performed routinely during follow-up of WD, unless clinically indicated, the progression and timing of the liver pathology is characterized poorly. Previous studies have shown the possibility of improvement during long-term follow-up of the steatosis and inflammation grade, and of the fibrosis stage. Studies on serial liver biopsies, as well as studies on the correlation between hepatic histology and clinical parameters are lacking.

**Research frontiers**

The research hotspots are: (1) what is the rate of hepatic fibrosis progression in WD; and (2) when is the best time to perform follow-up liver biopsies in WD patients?

**Innovations and breakthroughs**

The results indicate that the estimated rate of progression of hepatic fibrosis (as result of the mean difference in fibrosis scores divided by the mean interval in years between the first and second liver biopsies) in the entire WD group was 0 units per year between the first and second liver biopsy (4 years), and 0.25 between the second and third (3 years). However, among progressors the rate of progression of liver fibrosis was estimated as 0.23 and 0.6 fibrosis units per year between the first and second biopsy and between the second and third, respectively.

**Applications**

The results suggest that liver biopsy with hepatic copper quantification every 3 years should be considered.

**Peer review**

This paper investigate the progression of hepatic histopathology in serial liver biopsies from WD patients. The manuscript is well written, and it can be published in current form.

**REFERENCES**

1. Frydmann M. Genetic aspects of Wilson's disease. J Gastroenterol Hepatol 1990; 5: 483-490
2. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-337
3. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344-350
4. Medici V, Rossaro L, Sturniolo GC. Wilson disease--a practical approach to diagnosis, treatment and follow-up. Dig Liver Dis 2007; 39: 601-609
5. Guan R, Oon CJ, Wong PK, Foong WC, Wee A. Primary hepatocellular carcinoma associated with Wilson's disease in a young woman. Postgrad Med J 1985; 61: 357-359
6. Ludwig J, Moyer TP, Rakela J. The liver biopsy diagnosis of Wilson's disease. Methods in pathology. Am J Clin Pathol
Cope-Yokoyama S et al. Wilson disease and histopathological progression

1994;102:443-446
7 Stromeyer FW, Ishak KG. Histology of the liver in Wilson's disease: a study of 34 cases. Am J Clin Pathol 1980;73:12-24
8 Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology 1968;55:354-367
9 Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089-2111
10 Medici V, Trevisan CP, D’Incà R, Barollo M, Zancan L, Fagioli S, Martines D, Irato P, Sturoni GC. Diagnosis and management of Wilson's disease: results of a single center experience. J Clin Gastroenterol 2006;40:936-941
11 Sturoni GC, Mestriner C, Irato P, Albergoni V, Longo G, D’Incà R. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson’s disease patients. Am J Gastroenterol 1999;94:334-338
12 Marcellini M, Di Ciommo V, Callea F, Devito R, Compacolla D, Sartorelli MR, Carelli G, Nobili V. Treatment of Wilson’s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med 2005;145:139-143
13 Askari FK, Greeneson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003;142:385-390
14 Linn FH, Houwen RH, van Hattum J, van der Kleij S, van Erpecum KJ. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 2009;50:1442-1452
15 Searle J, Kerr JFR, Halliday JW, Powell LW. Iron storage disease. In: MacSween RNM, Anthony PP, Scheuer PJ, Portmann BC, Burt AD, editors. Pathology of the liver. 3rd ed. Churchill Livingstone: Edinburgh, 1994:219-241
16 D’agostino RB, Stephens M. Goodness-of-Fit Techniques, 2nd ed. New York: Marcel Dekker, Inc, 1986
17 Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007;56:115-120
18 Grand RJ, Vawter GF. Juvenile Wilson disease: histologic and functional studies during penicillamine therapy. J Pediatr 1975;87:1161-1170
19 Sternlieb I, Feldmann G. Effects of anticyper therapy on hepatocellular mitochondria in patients with Wilson’s disease: an ultrastructural and stereological study. Gastroenterology 1976;71:457-461
20 Shiono Y, Wakisawa S, Hayashi H, Takikawa T, Yano M, Okada T, Mabuchi H, Kono S, Miyajima H. Iron accumulation in the liver of male patients with Wilson’s disease. Am J Gastroenterol 2001;96:3147-3151
21 Iorio R, D’Ambrosi M, Marcellini M, Barbera C, Maggiore G, Zancan L, Giachino R, Vajro P, Marazzi MG, Francavilla R, Michielutti F, Resti M, Fldiani T, Pastore M, Mazzarella G, Fusco G, Cirillo F, Vegnente A. Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr 2004;39:331-336
22 Iorio R, D’Ambrosi M, Marcellini M, Barbera C, Maggiore G, Zancan L, Giachino R, Vajro P, Marazzi MG, Francavilla R, Michielutti F, Resti M, Fldiani T, Pastore M, Vegnente A. Persistence of elevated aminotransferases in Wilson’s disease despite adequate therapy. Hepatology 2004;39:1173-1174
23 Goldfischer S, Sternlieb I. Changes in the distribution of hepatic copper in relation to the progression of Wilson’s disease (hepatolenticular degeneration). Am J Pathol 1968;53:883-901
24 Faa G, Nurchi V, Demelia L, Ambu R, Parodo G, Congiu T, Sciotti R, Van Eyken P, Silvagni R, Crispolini G. Uneven hepatic copper distribution in Wilson’s disease. J Hepatol 1995;22:303-308

S-Editor Wang JL  L-Editor Kerr C  E-Editor Ma WH